Ann: PAT-DX1 Active in Pre-clinical Cancer Models, page-129

Not sure why people are talking about FDA approval or anything like that.

The ability of DX1 to penetrate the cell and bind directly to the DNA as opposed to the surface is HUGE - this will deal out long before it see's clinic in PAB's hands - stability, PK/PD, toxicology, formulation that's probably about all PAB will get to before it's taken out. The potential to work synergistically with PARP and other inhibitors only ups the stakes. It's a super hot space they are walking into with pharma in fierce competition amongst each other and yes big deals are being stitched here preclinical as long as it's showing suitors what they want to see to keep ahead of their peers. Still ridiculous at just $15M.